RECOVER-TLC announces public comment period for upcoming clinical trial
Members of the public can provide comments on a clinical trial testing the safety and effectiveness of a drug that could help treat Long COVID in adults and children aged 12 and older.
RECOVER-Treating Long COVID (RECOVER-TLC) invites patients, caregivers, advocates, healthcare providers, and researchers to provide feedback on the draft protocol synopsis for its upcoming glucagon-like peptide-1 receptor agonist (GLP-1 RA) clinical trial. This draft protocol synopsis (study plan summary) contains information about the questions the study will investigate, how researchers will look for answers, and who can join the study.
About the treatment to be studied
GLP-1 receptor agonists (GLP-1 RAs) are drugs that are currently used as treatments for diabetes and obesity. Because GLP-1 RAs may also help reduce inflammation and immune dysregulation, RECOVER-TLC plans to study them as possible treatments for a variety of Long COVID symptoms. RECOVER-TLC also plans to enroll both adults and adolescents (children aged 12 years and older) in this trial.
How to provide feedback
The draft GLP-1 RA protocol synopsis and comment submission form will be made available on the RECOVER-TLC Collaborator Portal on April 8 and will remain accessible until 11:59 pm ET on April 24.
Comments should address the GLP-1 RA trial’s feasibility (how likely it is the study will produce valuable results), accessibility (how easy it will be for people affected by Long COVID to participate in the study), and how well the trial’s design reflects the Long COVID community’s needs and priorities.
Anyone who does not have an account and would like to become a public commenter can register through the RECOVER-TLC Collaborator Portal. Anyone who would like to comment and is already registered will not need to register again. All registered portal users will receive an email once the protocol synopsis is available for public comment.
For help with any issues registering through or using the RECOVER-TLC Collaborator Portal, please email recover-tlc@rti.org.